المؤلفون: Z. W. Hawks, E. D. Beck, L. Jung, L. M. Fonseca, M. J. Sliwinski, R. S. Weinstock, E. Grinspoon, I. Xu, R. W. Strong, S. Singh, H. P. A. Van Dongen, M. R. Frumkin, J. Bulger, M. J. Cleveland, K. Janess, Y. C. Kudva, R. Pratley, M. R. Rickels, S. R. Rizvi, N. S. Chaytor, L. T. Germine

المصدر: npj Digital Medicine, Vol 7, Iss 1, Pp 1-13 (2024)

مصطلحات موضوعية: Computer applications to medicine. Medical informatics, R858-859.7

الوصف: Abstract Type 1 diabetes (T1D) is a chronic condition characterized by glucose fluctuations. Laboratory studies suggest that cognition is reduced when glucose is very low (hypoglycemia) and very high (hyperglycemia). Until recently, technological limitations prevented researchers from understanding how naturally-occurring glucose fluctuations impact cognitive fluctuations. This study leveraged advances in continuous glucose monitoring (CGM) and cognitive ecological momentary assessment (EMA) to characterize dynamic, within-person associations between glucose and cognition in naturalistic environments. Using CGM and EMA, we obtained intensive longitudinal measurements of glucose and cognition (processing speed, sustained attention) in 200 adults with T1D. First, we used hierarchical Bayesian modeling to estimate dynamic, within-person associations between glucose and cognition. Consistent with laboratory studies, we hypothesized that cognitive performance would be reduced at low and high glucose, reflecting cognitive vulnerability to glucose fluctuations. Second, we used data-driven lasso regression to identify clinical characteristics that predicted individual differences in cognitive vulnerability to glucose fluctuations. Large glucose fluctuations were associated with slower and less accurate processing speed, although slight glucose elevations (relative to person-level means) were associated with faster processing speed. Glucose fluctuations were not related to sustained attention. Seven clinical characteristics predicted individual differences in cognitive vulnerability to glucose fluctuations: age, time in hypoglycemia, lifetime severe hypoglycemic events, microvascular complications, glucose variability, fatigue, and neck circumference. Results establish the impact of glucose on processing speed in naturalistic environments, suggest that minimizing glucose fluctuations is important for optimizing processing speed, and identify several clinical characteristics that may exacerbate cognitive vulnerability to glucose fluctuations.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2398-6352Test

الوصول الحر: https://doaj.org/article/c3e55525fc5b41ed826807083ae07618Test

المؤلفون: K W Mahaffey, F M M Baeres, G Bakris, H Bosch-Traberg, M Gislum, J Lawson, J F E Mann, H Mersebach, V Perkovic, P Rossing, K Tuttle, R Pratley

المصدر: European Heart Journal. 43

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Background Patients with chronic kidney disease and type 2 diabetes (T2D) have a high risk of progression to kidney failure as well as cardiovascular (CV) events. It is established that glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and reduce body weight. Some CV outcomes trials have shown that GLP-1RAs reduce CV risk in people with T2D at high CV risk; for example, the SUSTAIN 6 trial demonstrated that the GLP-1RA semaglutide significantly lowered the rate of major CV events (CV death, non-fatal myocardial infarction and non-fatal stroke) versus placebo. Some trials have also indicated that GLP-1RAs reduce albuminuria and estimated glomerular filtration rate (eGFR) decline. Based on these previous results indicating potential kidney-protective effects, the FLOW trial (NCT03819153) is evaluating once-weekly, subcutaneous semaglutide 1.0 mg versus placebo on kidney- and CV-related outcomes in participants with T2D. We describe the baseline characteristics and the calculated CV risk of this patient population using the atherosclerotic CV disease (ASCVD) and second manifestations of arterial disease (SMART) risk calculators. Methods FLOW is an ongoing, multicentre, randomised, double-blind, parallel-group, event-driven, phase 3b trial, with participants randomised 1:1 to semaglutide or placebo, each in addition to standard of care. Recruitment is complete and 3,535 participants with T2D, an eGFR ≥25–≤75 mL/min/1.73 m2, and urine albumin-to-creatinine ratio ≥100–≤5,000 mg/g have been enrolled. The primary endpoint is time to first occurrence of a kidney composite that includes ≥50% persistent eGFR reduction, kidney failure (persistent eGFR Results The baseline clinical characteristics and demographics are shown (Table 1). Median age was 68 years, 30% were female, mean diabetes duration was 17 years, and 98% had a history of hypertension. Overall, 52% of participants had a previous CV event. The calculated 10-year risk for ASCVD events in those without prior ASCVD was 31% in males and 18% in females, and in those with previous CV events was 37–56% in males and 35–53% in females depending on the type of CV disease reported in the calculator (Table 2). Conclusions The FLOW trial has completed enrolment. Based on the ASCVD and SMART risk calculators, the enrolled population has a substantial risk for adverse CV outcomes. Event ascertainment is ongoing, and the FLOW trial will provide evidence for the potential of semaglutide to improve kidney and CV outcomes in the T2D population. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Novo Nordisk

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::687524aa5d8574039c4e26c8fc10dc26Test
https://doi.org/10.1093/eurheartj/ehac544.2617Test

المؤلفون: M Hauser, M Haluzik, R Bauer, J Eriksson, S Hoff, R Pratley, J Buse

المصدر: Präzisionsmedizin – Eine Reise in die Zukunft der Diabetologie www.diabeteskongress.de.

مصطلحات موضوعية: Diabetes duration, medicine.medical_specialty, business.industry, Semaglutide, Internal medicine, medicine, Subgroup analysis, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::a7c6572d6b690584deaa01c34fb17eb0Test
https://doi.org/10.1055/s-0041-1727309Test

المؤلفون: Robert Silver, G Bedel, M Yanovskaya, Simon Heller, T Hart, A Golovach, G Cornett, A Luts, A Chang, L Lewy-Alterbaum, H Nguyen, S Hasan, Amir Tirosh, W Biggs, R Pratley, K Blaze, Ole Holm Hels, A Peskov, P Houser, E Klein, Peter Rossing, H Knoble, T Milovanova, P O'Donnell, S Folkerth, H A Frandsen, S Chandran, A Krzeminski, Richard E. Pratley, J Reed, S Sulosaari, Torben Hansen, T Donner, Jan W. Eriksson, R Jackson, N Krasnopeeva, J Pouzar, E Kazakova, J Gumprecht, Thalia Marie Blicher, E Morawski, S Nieminen, Y Shlesinger, J Parker, Klaus Levin, T Maxwell, Z Shaikh, A Nikkola, E Zhdanova, D Nabriski, T Lysenko, P Norwood, G Vagapova, K Khan, J Eriksson, M Hellgren, Ofri Mosenzon, John Strand, M Hewitt, Naim Shehadeh, B Barker, E Haddad, K Eliasson, Y Pergaeva, T Sathyapalan, M Kunitsyna, Thozhukat Sathyapalan, W Gandy, J Soufer, S Chilka, J Lawhead, P Nicol, M Benson, A Odugbesan, S Aronoff, G Gatipon, R Abramof, L Gonzalez-Orozco, C Desouza, O Mosenzon, I Beshay, H Traylor, B Snyder, Robert S. Lindsay, A Cleland, K Metsärinne, Paweł Bogdański, K Forshaw, M Sergeeva-Kondrachenko, Cyrus Desouza, M Hitz, S Plevin, K Astamirova, N Uhlenius, R Huntley, D Alpenidze, B Delgado, L Zarutskaya, Signe Rosenlund, John A. McKnight, P Levin, E Frolova, S Heller, P E Jakobsen, A Kapoor, R Busch, S Chaidarun, L Connery, S Hietaniemi, Sten Madsbad, M. Shamkhalova, S Lindmark, B Hella, L Belousova, C Mbogua, L Kargina

المصدر: Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C, PIONEER 5 Investigators, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Hansen, T K, Hitz, M, Jakobsen, P E, Levin, K, Madsbad, S, Nguyen, H, Parker, J, Reed, J, Rossing, P, Yanovskaya, M, Zarutskaya, L & Zhdanova, E 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587Test(19)30192-5
Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C & PIONEER 5 Investigators 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587Test(19)30192-5

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Population, Glucagon-Like Peptides, Administration, Oral, 030209 endocrinology & metabolism, Type 2 diabetes, Placebo, Glucagon-Like Peptide-1 Receptor, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Diabetic Nephropathies, Renal Insufficiency, 030212 general & internal medicine, education, Aged, education.field_of_study, business.industry, Semaglutide, Middle Aged, medicine.disease, Discontinuation, Clinical trial, Treatment Outcome, Diabetes Mellitus, Type 2, Female, business

الوصف: Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment. Methods: This randomised, double-blind, phase 3a trial was undertaken at 88 sites in eight countries. Patients aged 18 years and older, with type 2 diabetes, an estimated glomerular filtration rate of 30–59 mL/min per 1·73 m2, and who had been receiving a stable dose of metformin or sulfonylurea, or both, or basal insulin with or without metformin for the past 90 days were eligible. Participants were randomly assigned (1:1) by use of an interactive web-response system, with stratification by glucose-lowering medication and renal function, to receive oral semaglutide (dose escalated to 14 mg once daily) or matching placebo for 26 weeks, in addition to background medication. Participants and site staff were masked to assignment. Two efficacy-related estimands were defined: treatment policy (regardless of treatment discontinuation or rescue medication) and trial product (on treatment without rescue medication) in all participants randomly assigned. Endpoints were change from baseline to week 26 in HbA1c (primary endpoint) and bodyweight (confirmatory secondary endpoint), assessed in all participants with sufficient data. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered on ClinicalTrials.gov, number NCT02827708, and the European Clinical Trials Registry, number EudraCT 2015-005326-19, and is now complete. Findings: Between Sept 20, 2016, and Sept 29, 2017, of 721 patients screened, 324 were eligible and randomly assigned to oral semaglutide (n=163) or placebo (n=161). Mean age at baseline was 70 years (SD 8), and 168 (52%) of participants were female. 133 (82%) participants in the oral semaglutide group and 141 (88%) in the placebo group completed 26 weeks on treatment. At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA1c (estimated mean change of −1·0 percentage point (SE 0·1; −11 mmol/mol [SE 0·8]) vs −0·2 percentage points (SE 0·1; −2 mmol/mol [SE 0·8]); estimated treatment difference [ETD]: −0·8 percentage points, 95% CI −1·0 to −0·6; p1c −1·1 percentage points (SE 0·1; −12 mmol/mol [SE 0·8] versus −0·1 percentage points (SE 0·1; −1 mmol/mol [SE 0·8]; ETD −1·0 percentage points, 95% CI −1·2 to −0·8; p

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d569511b15de88f728dd8364203edd9Test
https://curis.ku.dk/ws/files/251035512/Efficacy_and_safety_of_oral_semaglutide_in_patients_with_type_2_diabetes_and_moderate_renal_impairment_PIONEER_5_accepted_version_.pdfTest

المؤلفون: X., Yang, R., Pratley, S., Tokraks, C., Bogardus, P., Permana

المصدر: Diabetologia ; volume 45, issue 11, page 1584-1593 ; ISSN 0012-186X 1432-0428

مصطلحات موضوعية: Endocrinology, Diabetes and Metabolism, Internal Medicine

الإتاحة: https://doi.org/10.1007/s00125-002-0905-7Test

المؤلفون: R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, A. Garber, A. b. Thomsen, H. Hartvig, M. Davies, Lira Dpp Study Group, FILETTI, SEBASTIANO

المساهمون: R., Pratley, M., Nauck, T., Bailey, E., Montanya, R., Cuddihy, Filetti, Sebastiano, A., Garber, A. b., Thomsen, H., Hartvig, M., Davie, Lira Dpp Study, Group

الوصف: P>Aim: The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. Methods: In an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n = 225), liraglutide 1.8 mg/day (n = 221) or sitagliptin 100 mg/day (n = 219) for 26 weeks (main phase). Participants continued the same treatment in a 26-week extension. Results: Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively. Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p < 0.0001). Weight loss was greater with liraglutide 1.2 mg (-2.78 kg) and 1.8 mg (-3.68 kg) than sitagliptin (-1.16 kg) (both p < 0.0001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin (p = 0.03). Proportions of participants reporting adverse events were generally comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide 1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly nausea, initially occurred more frequently with liraglutide, but declined after several weeks. Conclusion: Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks. Treatment satisfaction was significantly greater with 1.8 mg liraglutide, similar to 26-week results. The safety profiles of liraglutide and sitagliptin are consistent with previous reports.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21355967; info:eu-repo/semantics/altIdentifier/wos/WOS:000288458300008; volume:65; issue:4; firstpage:397; lastpage:407; numberofpages:11; journal:INTERNATIONAL JOURNAL OF CLINICAL PRACTICE; http://hdl.handle.net/11573/357457Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-79952755181; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000288458300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest; http://www.scopus.com/inward/record.url?eid=2-s2.0-79952755181&partnerID=65&md5=a63f7c3872fe23687b186d3a68e4d385Test

الإتاحة: https://doi.org/10.1111/j.1742-1241.2011.02656.xTest
http://hdl.handle.net/11573/357457Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000288458300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest
http://www.scopus.com/inward/record.url?eid=2-s2.0-79952755181&partnerID=65&md5=a63f7c3872fe23687b186d3a68e4d385Test

المؤلفون: Melinda M. Manore, J S Skinner, R. Pratley, E Ravussin, M. B. Monroe, P. A. Tataranni

المصدر: The American Journal of Clinical Nutrition. 68:1223-1227

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Sympathetic nervous system, Medicine (miscellaneous), Physical exercise, Oxygen Consumption, Internal medicine, medicine, Humans, Exercise, Spinal cord injury, Spinal Cord Injuries, Nutrition and Dietetics, Chemistry, Control subjects, medicine.disease, Respiratory quotient, Autonomic nervous system, Endocrinology, medicine.anatomical_structure, Food, Basal metabolic rate, Physical therapy, Basal Metabolism, Specific dynamic action, Energy Intake, Energy Metabolism, Sleep, Body Temperature Regulation

الوصف: BACKGROUND This study was designed to determine the effect of chronic spinal cord injury on daily energy expenditure. OBJECTIVE We hypothesized that both resting and total energy expenditure would be lower in spinal cord-injured (SCI) subjects than in control subjects because of lower sympathetic nervous system activity and reduced levels of physical activity in SCI subjects. DESIGN Twenty-four-hour energy expenditure (24-h EE), resting metabolic rate (RMR), sleeping metabolic rate, spontaneous physical activity, the thermic effect of food (TEF), and 24-h respiratory quotient were measured by using a respiratory chamber in 10 male SCI subjects (injury ranged from level C6 to L3) and 59 age-matched, noninjured, male control subjects. RESULTS The 24-h EE was lower in SCI than in control subjects (7824 +/- 305 compared with 9941 +/- 188 kJ, P < 0.01). After adjustment for fat-free mass, fat mass, and age, 24-h EE was still lower (-753 kJ/d, P < 0.01) in SCI than in control subjects. Spontaneous physical activity measured by a radar system was also significantly lower (4.6 +/- 0.6% compared with 6.5 +/- 0.3% of time, P < 0.01) in SCI than in control subjects. In absolute value (7347 +/- 268 compared with 9251 +/- 1326 kJ/d, P < 0.01) or after adjustment for fat-free mass, fat mass, and age (-678 kJ/d, P < 0.01), RMR was also lower in SCI than in control subjects. TEF was significantly lower in SCI than in control subjects (987 +/- 142 compared with 1544 +/- 213 kJ/d, representing 12.9% and 15.9% of total energy intake, respectively, P < 0.05). The sleeping metabolic rate and 24-h respiratory quotient did not differ significantly between groups. CONCLUSIONS The 24-h EE was significantly lower in SCI than in control subjects. This difference can be explained by the lower levels of physical activity, and lower RMR and TEF values, in SCI subjects.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7296e28cdc298b0876c78d20ef6e3160Test
https://doi.org/10.1093/ajcn/68.6.1223Test

المؤلفون: R Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, A Garber, AB Thomsen, H Hartvig, M Davies, 1860-LIRA-DPP-4 Study Group

مصطلحات موضوعية: Uncategorized, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Fasting, Female, Glucagon-Like Peptide 1, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Liraglutide, Male, Metformin, Middle Aged, Pyrazines, Sitagliptin Phosphate, Treatment Outcome, Triazoles, Weight Loss

الوصف: AIM: The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. METHODS: In an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n=225), liraglutide 1.8 mg/day (n=221) or sitagliptin 100 mg/day (n=219) for 26 weeks (main phase). Participants continued the same treatment in a 26-week extension. RESULTS: Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively. Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p<0.0001). Weight loss was greater with liraglutide 1.2 mg (-2.78 kg) and 1.8 mg (-3.68 kg) than sitagliptin (-1.16 kg) (both p<0.0001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin (p=0.03). Proportions of participants reporting adverse events were generally comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide 1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly nausea, initially occurred more frequently with liraglutide, but declined after several weeks. CONCLUSION: Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks. Treatment satisfaction was significantly greater with 1.8 mg liraglutide, similar to 26-week results. The safety profiles of liraglutide and sitagliptin are consistent with previous reports.

العلاقة: 2381/44626; https://figshare.com/articles/journal_contribution/One_year_of_liraglutide_treatment_offers_sustained_and_more_effective_glycaemic_control_and_weight_reduction_compared_with_sitagliptin_both_in_combination_with_metformin_in_patients_with_type_2_diabetes_a_randomised_parallel-group_open-labe/10143560Test

الإتاحة: https://figshare.com/articles/journal_contribution/One_year_of_liraglutide_treatment_offers_sustained_and_more_effective_glycaemic_control_and_weight_reduction_compared_with_sitagliptin_both_in_combination_with_metformin_in_patients_with_type_2_diabetes_a_randomised_parallel-group_open-labe/10143560Test

المؤلفون: D. Gordon, R. Pratley

المصدر: MD Conference Express. 10:18-19

مصطلحات موضوعية: Lead (geology), Risk analysis (engineering), Environmental science

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b268b5c9188ec0e9981a0ede2636bbe3Test
https://doi.org/10.1177/155989771009004Test

المؤلفون: Ira D. Goldfine, R. Pratley, Jack F. Youngren

المصدر: Experimental and Clinical Endocrinology & Diabetes. 104:182-183

مصطلحات موضوعية: medicine.medical_specialty, biology, Chemistry, Endocrinology, Diabetes and Metabolism, General Medicine, Tropomyosin receptor kinase B, Tropomyosin receptor kinase C, IRS2, Insulin receptor, Endocrinology, Internal medicine, Insulin receptor substrate, Internal Medicine, medicine, biology.protein, Tyrosine kinase, Protein kinase B, Insulin-like growth factor 1 receptor

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0339fe08751d1e199ec120dd5e5d7603Test
https://doi.org/10.1055/s-0029-1211664Test